PubRank

A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma (CHIR-265-MEL01)

Clinical Trial ID NCT00304525

PubWeight™ 21.83‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00304525

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011 2.89
2 Ras in cancer and developmental diseases. Genes Cancer 2011 2.68
3 Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012 1.96
4 Melanoma: new insights and new therapies. J Invest Dermatol 2012 1.54
5 Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets 2007 1.44
6 Beyond BRAF: where next for melanoma therapy? Br J Cancer 2014 1.26
7 B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol 2013 1.14
8 Targeting the RAS oncogene. Expert Opin Ther Targets 2013 1.02
9 Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol 2013 0.99
10 BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget 2014 0.92
11 Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther 2014 0.92
12 Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. Oncogene 2015 0.90
13 Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol 2013 0.89
14 Targeting drivers of melanoma with synthetic small molecules and phytochemicals. Cancer Lett 2015 0.88
15 Metastatic melanoma - a review of current and future drugs. Drugs Context 2012 0.83
16 Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract 2011 0.79
17 Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma. ACS Med Chem Lett 2015 0.77
18 Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells. J Cell Mol Med 2015 0.75
Next 100